Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ultragenyx Reports Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
March 25, 2015 4:05 PM EDTNOVATO, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the fourth quarter and full-year ended December 31, 2014.
"This past year was transformative for Ultragenyx in our mission to advance novel therapeutics for patients with rare and ultra-rare diseases," said Emil D. Kakkis, Ph.D., M.D., Chief Executive Officer and President of Ultragenyx. "The completion of our initial public offering early in 2014 has provided us with the capital to... More
Ultragenyx Reports Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update
March 25, 2015 4:05 PM EDTNOVATO, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the fourth quarter and full-year ended December 31, 2014.
"This past year was transformative for Ultragenyx in our mission to advance novel therapeutics for patients with rare and ultra-rare diseases," said Emil D. Kakkis, Ph.D., M.D., Chief Executive Officer and President of Ultragenyx. "The completion of our initial public offering early in 2014 has provided us with the capital to... More
